American Society of Gene & Cell Therapy (ASGCT) 16th Annual Meeting

描述(申请人提供)：美国基因与细胞治疗学会(ASGCT)成立于1996年。ASGCT的使命是促进知识、意识和教育，从而发现和临床应用基因和细胞疗法来缓解人类疾病。我们的年会代表了协会的主要教育倡议。这份R13提案要求为受训人员提供旅费补助。我们超过四分之一的成员是正在接受培训的科学家，他们致力于开发临床适用的基因和基于细胞的技术。学员参加年会的原因是独特的教育计划、众多的学员旅行奖项，以及通过同行评审的学员卓越研究奖对杰出科学成就的认可。在过去的十年中，ASGCT提供了520项旅行补助金和69项研究奖，其中160项旅行补助金是在同一时期由NIH颁发的R13补助金提供的。旅行奖获得者的教育机会包括杰出的全体演讲者、最先进的科学 研讨会和教育会议，回顾当前对各种主题的想法。除了顶尖的科学家和临床医生，该项目还包括伦理学家和来自FDA、OBA和NIH的代表，因此年轻科学家可以深入了解与人类基因治疗和细胞治疗相关的合规和伦理问题。受训人员是口头摘要和海报演示的活跃演讲者，顶尖受训人员摘要在总统研讨会上得到表彰。ASGCT会议的规模(约1,600人参加)非常适合让年轻科学家接触该领域的领导者，同时也为受训人员在基因和细胞治疗领域的首要会议上展示他们的工作提供了机会。NIH对ASGCT年会的支持将使细胞和基因治疗领域的受训者继续获得教育和专业上的进步，此外还有与该领域的领导者建立网络的独特机会。

DESCRIPTION (provided by applicant): The American Society of Gene & Cell Therapy (ASGCT) was founded in 1996. ASGCT's mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. Our Annual Meeting represents the major educational initiative of the Society. This R13 proposal requests support for travel grants for trainees. Over 1/4 of our members are scientists in training working to develop clinically applicable gene and cell-based technologies. Trainee participation in the Annual Meeting is fostered by a distinctive educational program, numerous trainee travel awards, and recognition of outstanding scientific accomplishments through peer-reviewed trainee Excellence in Research Awards. Over the past decade, the ASGCT has offered 520 travel grants and 69 Research Awards, with 160 travel grants made possible by R13 grant awards from the NIH during that same time. Educational opportunities for travel awardees include exceptional plenary speakers, state-of-the-art scientific symposia, and educational sessions that review current thinking on a variety of topics. In addition to leading scientists and clinicians, the program includes ethicists and representatives from the FDA, OBA, and NIH so young scientists may gain insight into the compliance and ethical issues related to human gene therapy and cell therapy. Trainees are active presenters in oral abstract and poster presentations and the top trainee abstracts are recognized at the Presidential Symposium. The size of the ASGCT meeting (approximately 1,600 participants) is ideally suited to expose young scientists to leaders in the field, yet provide opportunities for trainees to present their work at the premier meeting in the field of gene and cell therapy. NIH support for the ASGCT Annual Meeting will allow continued educational and professional advancement of trainees in the field of cell and gene therapy in addition to the unique opportunity to network with leaders in the field.